Disc Medicine, Inc. (NASDAQ:IRON) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its holdings in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 13.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 160,554 shares of the company’s stock after acquiring an additional 19,401 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.54% of Disc Medicine worth $7,890,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Amalgamated Bank boosted its position in shares of Disc Medicine by 76.9% during the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock worth $26,000 after buying an additional 247 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Disc Medicine by 45.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock worth $54,000 after purchasing an additional 337 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Disc Medicine during the second quarter worth about $129,000. Quest Partners LLC acquired a new position in Disc Medicine in the 3rd quarter valued at about $131,000. Finally, SG Americas Securities LLC increased its position in Disc Medicine by 44.2% in the 2nd quarter. SG Americas Securities LLC now owns 4,071 shares of the company’s stock valued at $183,000 after acquiring an additional 1,247 shares during the period. Institutional investors and hedge funds own 83.70% of the company’s stock.

Disc Medicine Stock Performance

Shares of NASDAQ:IRON opened at $67.47 on Wednesday. The company has a market capitalization of $2.01 billion, a PE ratio of -16.95 and a beta of 0.75. Disc Medicine, Inc. has a 52 week low of $25.60 and a 52 week high of $77.60. The company has a 50 day moving average price of $56.26 and a two-hundred day moving average price of $49.06.

Disc Medicine (NASDAQ:IRON) last announced its earnings results on Tuesday, November 12th. The company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($1.04) by $0.15. On average, sell-side analysts forecast that Disc Medicine, Inc. will post -4.05 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director William Richard White sold 1,957 shares of Disc Medicine stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $64.63, for a total transaction of $126,480.91. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider William Jacob Savage sold 14,183 shares of Disc Medicine stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $65.45, for a total transaction of $928,277.35. Following the sale, the insider now directly owns 40,405 shares in the company, valued at $2,644,507.25. This trade represents a 25.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 32,836 shares of company stock worth $2,038,816 in the last quarter. 4.24% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

IRON has been the topic of several research analyst reports. Morgan Stanley raised Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price target on the stock in a research note on Tuesday, November 5th. Jefferies Financial Group assumed coverage on Disc Medicine in a report on Wednesday, October 23rd. They issued a “buy” rating and a $89.00 price target for the company. Raymond James upgraded Disc Medicine from an “outperform” rating to a “strong-buy” rating and upped their price objective for the stock from $66.00 to $110.00 in a report on Monday, November 4th. Wedbush reiterated an “outperform” rating and issued a $83.00 price target on shares of Disc Medicine in a report on Monday. Finally, Wells Fargo & Company initiated coverage on shares of Disc Medicine in a research report on Thursday, August 22nd. They issued an “overweight” rating and a $75.00 price objective for the company. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Disc Medicine has a consensus rating of “Buy” and a consensus target price of $87.50.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.